Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Advancing Novel Therapeutics and Functional Outcomes in Pediatric CNS Tumors through National Clinical Trials Leadership, Innovative Trial Development and Mentorship

Award Number: R50CA318287
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/06/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Advancing Novel Therapeutics and Functional Outcomes in Pediatric CNS Tumors through National Clinical Trials Leadership, Innovative Trial Development and Mentorship - Abstract Pediatric central nervous system (CNS) tumors are among the most challenging childhood cancers, representing a leading cause of cancer-related mortality and long-term disability in survivors. This application seeks additional support to expand and accelerate clinical trial research in pediatric neuro-oncology, with a focus on translating molecular discoveries and novel therapeutic agents into effective clinical trials. These trials will not only focus on response and survival, but they will also prioritize patient reported outcomes, quality of life, and functional outcomes (i.e., motor, vision). Jason Fangusaro, MD, is Professor of Pediatrics and Director of Developmental Therapeutics at Children’s Healthcare of Atlanta and Emory University. Dr. Fangusaro leads institutional and national efforts to improve access to early-phase trials, including serving as the local Principal Investigator for the NCI-funded Pediatric Early Phase Clinical Trials Network (PEP-CTN). Nationally, Dr. Fangusaro contributes to the design and oversight of multiple trials through leadership roles, both past and present – notably, he has served as national Vice Chair of the Pediatric Brain Tumor Consortium (PBTC) and as a Steering Committee member of the Children’s Oncology Group (COG) CNS discipline. Over the next five years, Dr. Fangusaro will promote the following: a) expand the development of innovative early phase clinical trials through his leadership roles within the Developmental Therapeutics Program at the Aflac Cancer & Blood Disorders Center and the COG CNS Steering committee; b) promote the advancement of novel therapies with an emphasis on functional and quality of life outcomes; c) harness his role as the PI of the local Peach Bowl LegACy Fund to foster the development of focused early phase clinical trials to increase the pipeline for potential larger studies through the NCI-sponsored consortia (including the COG and COG PEP-CTN); and finally, d) focus on mentoring junior clinical trial oncology research faculty, both locally and nationally to help promote the next generation of clinical trialists. His work will address a vital need to develop and implement biologically driven, less toxic treatment strategies that improve both survival and long-term quality of life. Support through the R50 mechanism will provide protected time to expand national trial leadership, foster multidisciplinary collaboration, mentor junior investigators, and improve trial efficiency and access. Ultimately, Dr. Fangusaro is committed to ensuring that all children with CNS tumors benefit from cutting-edge therapies that enhance both survival and long-term neurodevelopmental outcomes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $196,792 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	1	8/6/2026	NEW	$196,792
														Subtotal = $196,792

Grand Total All Awards = $196,792

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing Novel Therapeutics and Functional Outcomes in Pediatric CNS Tumors through National Clinical Trials Leadership, Innovative Trial Development and Mentorship

Award Number: R50CA318287

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/06/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer